A government-wide hiring freeze and halt to funding of travel, meetings and communications have officials at the National ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...